Preclinical Development of Bortezomib (VELCADE

[1]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[2]  A. Arlt,et al.  Autocrine Production of Interleukin 1β Confers Constitutive Nuclear Factor κB Activity and Chemoresistance in Pancreatic Carcinoma Cell Lines , 2002 .

[3]  J. Adams.  Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[4]  R. Meyn,et al.  Protease inhibitors restore radiation‐induced apoptosis to Bcl‐2‐expressing lymphoma cells , 2001, International journal of cancer.

[5]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[6]  P. Richardson,et al.  Novel therapies targeting the myeloma cell and its bone marrow microenvironment. , 2001, Seminars in oncology.

[7]  J. Berenson,et al.  The role of nuclear factor-?b in the biology and treatment of multiple myeloma , 2001 .

[8]  D. Howard,et al.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. , 2001, Blood.

[9]  H. Withers,et al.  Molecular Pathways That Modify Tumor Radiation Response , 2001, American journal of clinical oncology.

[10]  R. Bold,et al.  Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. , 2001, The Journal of surgical research.

[11]  A. Hunter,et al.  Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an ∼700 kDa Apaf-1 containing apoptosome complex , 2001, Leukemia.

[12]  Wei Ping Wang,et al.  Inhibition of proteasome function induced apoptosis in gastric cancer , 2001 .

[13]  P. Richardson,et al.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.

[14]  K. Pienta.  Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. , 2001, Seminars in oncology.

[15]  D. S. Lind,et al.  Nuclear factor-κB is upregulated in colorectal cancer , 2001 .

[16]  P. Elliott,et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer , 2001, Journal of cellular biochemistry.

[17]  S. Ikehara,et al.  Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. , 2001, Oncology reports.

[18]  B. Aggarwal,et al.  Antiproliferative Effects of IFN-α Correlate with the Downregulation of Nuclear Factor-κB in Human Burkitt Lymphoma Daudi Cells , 2001 .

[19]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[20]  Z Chen,et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[22]  D. Delia,et al.  The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI , 2001, British journal of haematology.

[23]  C. Watson,et al.  p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells , 2001, Cell Death and Differentiation.

[24]  C. Van Waes,et al.  Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  P. Krammer,et al.  Proteasome Inhibitor‐Induced Apoptosis of Glioma Cells Involves the Processing of Multiple Caspases and Cytochrome c Release , 2000, Journal of neurochemistry.

[26]  W. Dalton,et al.  The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance , 2000, Current opinion in oncology.

[27]  G. Emons,et al.  Luteinizing Hormone-Releasing Hormone Induces Nuclear Factorκ B-Activation and Inhibits Apoptosis in Ovarian Cancer Cells , 2000 .

[28]  Steffen Hauptmann,et al.  Proteasome inhibitors induce caspase‐dependent apoptosis and accumulationof p21WAF1/Cip1 in human immatureleukemic cells , 2000 .

[29]  P. Elliott,et al.  Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  S-G Hwang,et al.  Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.

[31]  W. McBride,et al.  Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. , 2000, International journal of radiation oncology, biology, physics.

[32]  P. Elliott,et al.  Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.

[33]  A. Tomida,et al.  Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. , 2000, Cancer research.

[34]  C. Gélinas,et al.  The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL , 2000, Molecular and Cellular Biology.

[35]  C. Scheidereit,et al.  Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells , 2000, Leukemia.

[36]  E. Schattner,et al.  Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells1 , 2000, The Journal of Immunology.

[37]  W. Risau,et al.  Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  L. Bergmann,et al.  Normal Structure of NFKB 2, C-REL and BCL-3 Gene Loci in Lymphoproliferative and Myeloproliferative Disorders , 2000, Leukemia & lymphoma.

[39]  C. N. Coleman,et al.  Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen , 1999, Oncogene.

[40]  A. Waage,et al.  Apoptosis, proliferation and NF‐κB activation induced by agonistic Fas antibodies in the human myeloma cell line OH‐2: amplification of Fas‐mediated apoptosis by tumor necrosis factor , 1999, European journal of haematology.

[41]  V. Baldin,et al.  Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. , 1999, Biochemical and biophysical research communications.

[42]  R. Herbst,et al.  The proteasome inhibitor PS-341 in cancer therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  Marty W. Mayo,et al.  NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis , 1999, Molecular and Cellular Biology.

[44]  J. Cusack,et al.  NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[45]  S Omura,et al.  Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin , 1999, British journal of haematology.

[46]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[47]  B. Barlogie,et al.  Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.

[48]  M. Tomonaga,et al.  Constitutive Activation of NF-κB in Primary Adult T-Cell Leukemia Cells , 1999 .

[49]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[50]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[51]  T. McDonnell,et al.  Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53 , 1998, Oncogene.

[52]  K. Kliche,et al.  Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. , 1998, Blood.

[53]  M. Grever,et al.  Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.

[54]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[55]  S Omura,et al.  The proteasome is involved in angiogenesis. , 1998, Biochemical and biophysical research communications.

[56]  S. Ōmura,et al.  The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. , 1998, British Journal of Cancer.

[57]  L. Dick,et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.

[58]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[59]  G. Sledge,et al.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.

[60]  A. Goldberg,et al.  Proteasomes play an essential role in thymocyte apoptosis. , 1996, The EMBO journal.

[61]  J. Martinou,et al.  Involvement of the proteasome in the programmed cell death of NGF‐deprived sympathetic neurons. , 1996, The EMBO journal.

[62]  B. Dörken,et al.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. , 1996, Blood.

[63]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[64]  M. Schmitt,et al.  Inhibition of NF-KB-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAl-1 , 1995 .

[65]  J. Roth,et al.  Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. , 1995, Oncogene.

[66]  V. Castronovo,et al.  The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. , 1994, Biochemical pharmacology.

[67]  J. Wolchok,et al.  Activation of NF‐κB may be necessary but is not sufficient for induction of H‐2 antigens by TNF in J558L murine myeloma cells , 1994, Journal of leukocyte biology.

[68]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[69]  K. Tanaka,et al.  Abnormally high expression of proteasomes in human leukemic cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[70]  A. Kajdacsy-Balla,et al.  The role of constitutive NF-κB activity in PC-3 human prostate cancer cell invasive behavior , 2004, Clinical & Experimental Metastasis.

[71]  T. Slaga,et al.  The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. , 2002, Journal of cell science.

[72]  A. Goldberg,et al.  Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.

[73]  T. Hideshima,et al.  The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. , 2001, Oncogene.

[74]  L. Neckers,et al.  Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. , 2001, Cellular and molecular biology.

[75]  P. Elliott,et al.  Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. , 2001, International journal of radiation oncology, biology, physics.

[76]  Wim H. M. Saris,et al.  Proceedings of the American Association for Cancer Research. , 2001 .

[77]  J. Berenson,et al.  The Role of Nuclear Factor-KB in the Biology and Treatment of Multiple Myeloma , 2001 .

[78]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .